Research progress in the developmental process of non-viral CAR-T technology.
- Author:
Haipeng LI
1
;
Qiyu ZHU
2
;
Jialiang ZHU
3
;
Jingting MIN
4
Author Information
1. School of Mental Health, Bengbu Medical University, Bengbu, 233030, China.
2. School of Life Sciences, Bengbu Medical University, Bengbu, 233030, China.
3. School of Clinical Medicine, Bengbu Medical University, Bengbu, 233030, China.
4. School of Basic Medical Sciences Department of Human Anatomy, Bengbu Medical University, Bengbu, 233030, China. *Corresponding author, E-mail: 4291187362@qq.com.
- Publication Type:English Abstract
- MeSH:
Humans;
Immunotherapy, Adoptive/methods*;
Receptors, Chimeric Antigen/immunology*;
Animals;
Gene Transfer Techniques;
Genetic Vectors/genetics*;
Gene Editing;
CRISPR-Cas Systems/genetics*;
DNA Transposable Elements/genetics*;
T-Lymphocytes/immunology*;
Neoplasms/immunology*
- From:
Chinese Journal of Cellular and Molecular Immunology
2025;41(5):461-467
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T (CAR-T) lymphocytes are at the forefront of adoptive immunotherapy research, and this technology has significantly advanced the prospects of tumor immunotherapy. CAR-T therapy has demonstrated remarkable efficacy in haematological tumours of lymphoid origin and provided therapeutic possibility for solid tumours. Currently, CAR-T cell preparation predominantly involves transfection of T cells with viral vectors. However, the production of viral vectors is time-consuming, expensive, and the vectors have low loading capacity, along with insertion instability. Consequently, there is a pressing need to develop more convenient and precise non-viral gene delivery methods. This paper reviews the most promising non-viral gene delivery technologies, including CRISPR/Cas9 gene editing, transposon systems such as Sleeping Beauty (SB) and PiggyBac (PB), and mRNA, and anticipates the future development of non-viral vector-based CAR-T therapies.
